GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bionoid Pharma Inc (OTCPK:BINP) » Definitions » Debt-to-Equity

Bionoid Pharma (Bionoid Pharma) Debt-to-Equity : -0.02 (As of Mar. 2011)


View and export this data going back to 2007. Start your Free Trial

What is Bionoid Pharma Debt-to-Equity?

Bionoid Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2011 was $0.04 Mil. Bionoid Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2011 was $0.00 Mil. Bionoid Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2011 was $-1.48 Mil. Bionoid Pharma's debt to equity for the quarter that ended in Mar. 2011 was -0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bionoid Pharma's Debt-to-Equity or its related term are showing as below:

BINP's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Bionoid Pharma Debt-to-Equity Historical Data

The historical data trend for Bionoid Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionoid Pharma Debt-to-Equity Chart

Bionoid Pharma Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10
Debt-to-Equity
-0.91 -0.67 -0.53 -0.15 -0.25

Bionoid Pharma Quarterly Data
Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.20 -0.13 -0.25 -0.02

Competitive Comparison of Bionoid Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Bionoid Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionoid Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bionoid Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bionoid Pharma's Debt-to-Equity falls into.



Bionoid Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bionoid Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2010 is calculated as

Bionoid Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2011 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionoid Pharma  (OTCPK:BINP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Bionoid Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bionoid Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionoid Pharma (Bionoid Pharma) Business Description

Traded in Other Exchanges
N/A
Address
433 N Camden Dr, Beverly Hills, CA, USA, 90210
Bionoid Pharma Inc is a cannabis company that cultivates, extracts, tests, and distributes organic hemp, cannabinoid, and related products. Its products aid in decreasing pain, improving recovery time, enhancing performance, and enhance physical well-being.